肿瘤药物的价值是什么？

What is the value of oncology medicines?

机构信息

Tufts University School of Medicine, Center for the Study of Drug Development, Boston, Massachusetts, USA.

出版信息

Nat Biotechnol. 2010 Nov;28(11):1160-3. doi: 10.1038/nbt1110-1160.

Abstract

Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.

摘要

采用基于证据的开发覆盖（CED），而不是质量调整生命年（QALY）阈值，为在平衡新肿瘤学产品的循证政策与开发者、支付者、医生和患者的需求方面提供了最佳途径。